Gastric carcinoma and colonic cancer
Conditions
Interventions
Group B:FOLFOX4 course will be used: 85 mg/m2 OXA
Group A:Orally giving "Yiqi yangyin" granul from one week before the chemotherapy to the participants. 100ml water solving one bag of granul, three times a day, totally 6 weeks, to the second week aft
Sponsors
The General Hospital of Fuzhou Army District
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. patients with II and III stages (according to NCCN guideline 2008) gastric carcinoma and colonic cancer diagnosed by histopathology, accepted RO section treatment, without tumour focus; 2. Allow to accept the chemotherapy; 3. Aged 18 to 75; 4. KPS >=70; 5. Expected survival >=6 months; 6. Normal presentation of Blood cell count, liver function, renal function and ECG; 7. No any other tumour history, except skin cancer and cervical carcinoma; 8. Not used other anti-tumour drugs and the drugs can influence boold cell, immun function, include "Buyi" TCMs; 9. Signed consent form.
Exclusion criteria
Exclusion criteria: 1. allergic history for treatment drugs; 2. WBC=<3.5*10^9/L or neutrophillic granulocyte<1.5*10^9/L, Hb<80g/L, Plt<80*10^9/L; 3. ALT or AST higher than upper threshold 2.5 times, bilirubin concentration higher than upper threshold 2.5 times, BUN and Gr concentration than upper threshold 1.5 times; 4. Needs to be venous inject blood products such as red cell or albumin, etc. 5. Complicated with immun system diseases, or uncontrolled sever internal diseases or acute infections, life threatenning on due treatment; 6. Upper degistive tract physiological function deficiency, absorption function deficiency or unable orally take drugs; degistive tract bleeding; 7. Use other drugs during the treatment; 8. In last three monthes participated other new drug clinical trials; 9. Breast feeding or pregnancy woman; 10. Had accepted organ translation; 11. Researchers in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life;Mortality;Disease free survival;Concentration of CD3+, CD4+, CD4+/ CD8+, NK cell, Immuknow, IL-2, INF-r; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of chemetherapy;Assessment of physical strenth; | — |
Countries
China
Contacts
Public ContactJian Du
Outcome results
None listed